Spinbionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0001072497, NIP 9721346644) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. Spinbionic operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since November 30, 2023. Spinbionic's most recently reported net revenue was 211.3 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Spinbionic
Identity
- Name
- Spinbionic Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- November 30, 2023
- Registry status as of
- July 3, 2026
- Latest entry
- July 3, 2026
- Founding act
- 05.10.2023 R., KANCELARIA NOTARIALNA MIKOŁAJ SIENNICKI - NOTARIUSZ, REP. A NR 11.692/2023
Articles of association history (1)
- October 5, 2023: 05.10.2023 R., KANCELARIA NOTARIALNA MIKOŁAJ SIENNICKI - NOTARIUSZ, REP. A NR 11.692/2023
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WSZECHNICY PIASTOWSKIEJ, 3, 1/21, 61-614, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-17748-67191-GWFBU-23
Risk and payment profile - Spinbionic
Credibility rating
69 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
2
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/3 yrs
Board changes
0
0/3 yrs
PKD changes
0
0/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Spinbionic
Founded
November 30, 2023
2 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
96 shares total
Shareholders
3
shareholders
Board
3 people
Filed years
1 year
2024
Registry entries
9
latest: July 3, 2026
Revenue
211.3 K PLN
2024
Net profit
76.5 K PLN
2024
Assets
99.1 K PLN
2024
Equity
81.5 K PLN
2024
Valuation
402.1 K PLN
Low confidence
Low confidence
Board and connected people - Spinbionic
People holding roles at Spinbionic according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Adam Aron MielochBoard member, Majority shareholder
- Filip Witold PorzucekBoard member, Majority shareholder
- Jakub Dalibor RybkaBoard member, Majority shareholder
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Spinbionic.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.